Press release
Migraine Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca
"Migraine Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.
The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Migraine Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years.
*
Migraine companies working in the treatment market are Axsome Therapeutics, Tonix Pharmaceuticals, Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment
*
Emerging Migraine therapies in the different phases of clinical trials are- TNX1900, LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.
*
In September 2025, Click Therapeutics, Inc., a pioneer in Digital Therapeutics Trademark , announced achieving the primary endpoint in the pivotal randomized, double-blind, controlled, decentralized ReMMi-D study (NCT05853900) evaluating CT-132 for migraine prevention. After 12 weeks of treatment, CT-132 demonstrated a statistically significant reduction in monthly migraine days (MMDs) compared to sham treatment (-0.9 MMDs, p=0.005) in the ITT population of 568 participants, with the treatment group experiencing a reduction of -3.04 MMDs by the study's conclusion.
*
In June 2025, Teva Pharmaceutical released the final results from the PEARL Phase IV trial evaluating Ajovy (fremanezumab), an anti-CGRP monoclonal antibody, for the prevention of chronic and episodic migraine (EM). The pan-European study successfully met both its primary and secondary endpoints. The primary objective was to determine the proportion of patients who achieved a minimum 50% reduction in monthly migraine days (MMD) within six months of initiating fremanezumab therapy.
*
In May 2025, The FDA has approved Satsuma's dihydroergotamine (DHE) nasal powder, STS101-now marketed as Atzumi-for the acute treatment of migraine, with or without aura, according to a company announcement. However, the company clarified that Atzumi is not approved for migraine prevention or for treating hemiplegic migraine or migraine with brainstem aura.
*
In April 2025, The US Food and Drug Administration (FDA) has approved CT-132 from Click Therapeutics, a first-of-its-kind prescription digital therapeutic designed to help prevent episodic migraine in adults. According to the company's announcement, this mobile smartphone application combines biological, psychological, and behavioral methods to influence pain perception. Features include a daily lesson program and an eDiary tracker. CT-132 is intended to be used in conjunction with existing acute and preventive migraine treatments.
Migraine Overview
Migraine is a neurological disorder characterized by recurring headaches, often on one side of the head, accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound. Migraines can occur with or without an aura, which are sensory disturbances like visual changes or tingling sensations that precede the headache. They are triggered by various factors, including stress, hormonal changes, certain foods, or environmental stimuli. While the exact cause is not fully understood, migraines are linked to genetic and environmental factors. Treatment includes pain relief medications, preventive therapies, and lifestyle modifications to reduce frequency and severity.
Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/migraine-pipeline-insight [https://www.delveinsight.com/report-store/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Migraine Drugs Under Different Phases of Clinical Development Include:
*
AXS-07: Axsome Therapeutics
*
TNX1900: Tonix Pharmaceuticals
*
LY3451838: Eli Lilly and Company
*
STS-101: Satsuma Pharmaceuticals
*
PUR-3100: Pulmatrix
*
UB-313: Vaxxinity, Inc.
*
TNX-1900: Tonix Pharmaceuticals, Inc
*
ABP-450: AEON Biopharma, Inc.
*
AXS 07: Axsome Therapeutics
*
Zavegepant: Pfizer
Migraine Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intra-articular
*
Intraocular
*
Intrathecal
*
Intravenous
*
Ophthalmic
*
Oral
*
Parenteral
*
Subcutaneous
*
Topical
*
Transdermal
Migraine Molecule Type
Migraine Products have been categorized under various Molecule types, such as
*
Oligonucleotide
*
Peptide
*
Small molecule
Migraine Pipeline Therapeutics Assessment
*
Migraine Assessment by Product Type
*
Migraine By Stage and Product Type
*
Migraine Assessment by Route of Administration
*
Migraine By Stage and Route of Administration
*
Migraine Assessment by Molecule Type
*
Migraine by Stage and Molecule Type
DelveInsight's Migraine Report covers around 30+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Migraine Therapeutics Market include:
Key companies developing therapies for Migraine are - GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.
Migraine Pipeline Analysis:
The Migraine pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
*
Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Migraine drugs and therapies [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Migraine Pipeline Market Drivers
*
Increasing prevalence of Migraine, significant progress is being made in the preventative treatment of chronic migraine, growing awareness regarding migraine are some of the important factors that are fueling the Migraine Market.
Migraine Pipeline Market Barriers
*
However, lack of proper diagnosis, various side-effects associated with the available drugs and other factors are creating obstacles in the Migraine Market growth.
Scope of Migraine Pipeline Drug Insight
*
Coverage: Global
*
Key Migraine Companies: Axsome Therapeutics, Tonix Pharmaceuticals, Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others
*
Key Migraine Therapies: TNX1900, LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others
*
Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
*
Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Migraine Report Introduction
2. Migraine Executive Summary
3. Migraine Overview
4. Migraine- Analytical Perspective In-depth Commercial Assessment
5. Migraine Pipeline Therapeutics
6. Migraine Late Stage Products (Phase II/III)
7. Migraine Mid Stage Products (Phase II)
8. Migraine Early Stage Products (Phase I)
9. Migraine Preclinical Stage Products
10. Migraine Therapeutics Assessment
11. Migraine Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Migraine Key Companies
14. Migraine Key Products
15. Migraine Unmet Needs
16 . Migraine Market Drivers and Barriers
17. Migraine Future Perspectives and Conclusion
18. Migraine Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=migraine-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-glaxosmithkline-merck-co-inc-pfizer-bausch-health-amgen-abbvie-inc-astrazeneca]
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca here
News-ID: 4218213 • Views: …
More Releases from ABNewswire
New YA Adventure "Milly and the Shawl of Athena" Transports Young Readers into a …
A gripping new teen and adventure novel has hit the shelves. Milly and the Shawl of Athena by J P Allen is a genre-defying novel which combines ancient mythology, gaming culture, and heart-wrenching family drama to produce an addictive adventure.
Set in a decade and inspired by the author's love of history, mythology, fiction, and computer games, this first in the planned series features twelve-year-old Milly Martin, whose ordinary life is…
Hudkins Publishing Music Launches Three Volumes of Background Music for Commerci …
Now they are available for every business.
KINGMAN, AZ - October 30, 2025 - Hudkins Publishing Music proudly announces the release of three new instrumental playlists explicitly designed for commercial use in cafes, offices, spas, restaurants, hotels, and creative studios. The new series-Hudkins Background Music Volumes 1-3-offers businesses royalty-free soundtracks that elevate atmosphere, encourage customer relaxation, and improve employee focus.
Each collection features 30 professionally produced instrumental tracks, available in both WAV…
Book Now the Emerging Gospel Artist "Jacqueline L. Jenkins" debuts new single "A …
BIOGRAPHY
Jacqueline L. Jenkins is an emerging gospel artist celebrated for her heartfelt lyrics and soulful vocals that blend traditional gospel spirit with contemporary rhythms. She first gained recognition with her debut single, "Thank You," which resonated deeply with listeners through its message of gratitude and faith. In 2024, Jacqueline released the Thank You - EP, featuring standout tracks such as "Going Home," a poignant tribute to her late mother, and…
Why More People Are Choosing Mobile Hair and Beauty Services Through DashStylist …
People are seeking a means of making their lives easier in the hectic world we all live in. Mobile beauty and hair services are one of the trends that are on the rise. These services help save time and efforts as the salon experience has been delivered to the home of the customer. Customers do not have to drive to a salon, wait until their turn comes and then drive…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
